Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171994
SEOM clinical guideline for treatment of kidney cancer (2017)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Matèries
Matèries (anglès)
Citació
Citació
GALLARDO, Enrique, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clinical & Translational Oncology. 2018. Vol. 20, num. 47-56. ISSN 1699-048X. [consulted: 29 of May of 2026]. Available at: https://hdl.handle.net/2445/171994